Status:
COMPLETED
Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)
Lead Sponsor:
Organon and Co
Conditions:
Bipolar Disorder
Schizophrenia
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®). The occurrence o...
Eligibility Criteria
Inclusion
- Inclusion Criteria for the Bipolar Disease Cohort:
- A diagnosis of Bipolar Disorder
- Exclusion Criteria for the Bipolar Disease Cohort:
- None
- Inclusion Criteria for the potential Schizophrenia Cohort:
- A diagnosis of schizophrenia
- Exclusion Criteria for the potential Schizophrenia Cohort:
- A prior and/or concomitant diagnosis of bipolar disease
Exclusion
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 18 2017
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01495741
Start Date
July 1 2013
End Date
December 18 2017
Last Update
February 4 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.